ClinicalTrials.gg
Enrolling by invitationNCT07949851SE-LINEUpdated Nov 19, 2026

A LINE Bot-Based Self-Efficacy Program to Improve Self-Management and Prevent Diabetic Ketoacidosis in Adolescents With Type 1 Diabetes

An interventional study of KidsCarb LINE Bot Self-Efficacy Program and Standard Nursing Care in Diabetic Ketoacidosis Children and Mobile Health, sponsored by Chulalongkorn University. Enrolling by invitation at 1 site in Thailand. Open to participants aged 13 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Chulalongkorn University · Not applicable, Interventional, and Treatment

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
13 Years to 18 Years
Sex
All
01

Study summary

Diabetic ketoacidosis (DKA) is a serious and potentially life-threatening complication of type 1 diabetes. Adolescents with type 1 diabetes need to perform daily self-management activities, such as taking insulin as prescribed, monitoring blood glucose levels, managing food intake, checking ketones when indicated, and responding appropriately to illness or abnormal blood glucose levels. However, maintaining these behaviors can be challenging during adolescence.

This study aims to evaluate the effect of a self-efficacy promoting program delivered through a LINE Bot (SE-LINE) on self-management behaviors to prevent diabetic ketoacidosis among adolescents with type 1 diabetes.

The program uses the LINE messaging application to provide educational information and learning activities designed to strengthen adolescents' confidence in their ability to manage diabetes. The program is based on the concept of self-efficacy and aims to support adolescents in developing the knowledge, confidence, and practical skills needed to perform appropriate diabetes self-management behaviors.

The study will assess changes in self-management behaviors related to DKA prevention before and after participation in the program. The findings may provide evidence on the use of a digital communication platform to support diabetes self-management among adolescents and inform the development of accessible nursing interventions for preventing DKA in this population.

Read the detailed description

Diabetic ketoacidosis (DKA) is an acute and potentially life-threatening complication of type 1 diabetes that can occur when there is insufficient insulin in the body. Prevention requires consistent diabetes self-management, including appropriate insulin administration, regular blood glucose monitoring, dietary management, recognition and management of abnormal blood glucose levels, ketone monitoring when indicated, and appropriate sick-day management.

Adolescents with type 1 diabetes face particular challenges in maintaining these behaviors because of developmental changes, increasing independence, and the demands of daily life. Self-efficacy, defined as an individual's confidence in their ability to perform specific behaviors, is an important factor that may influence their ability to manage diabetes consistently and respond appropriately to situations that increase the risk of DKA.

The SE-LINE program is designed to promote self-efficacy in diabetes self-management through the use of a LINE Bot. LINE is a widely used messaging application in Thailand and provides an accessible platform for delivering health-related information and supporting communication with adolescents.

The program is guided by Bandura's self-efficacy concept, which emphasizes the development of confidence through learning experiences and supportive feedback. The LINE Bot is used as a digital channel to deliver program content and learning activities intended to strengthen adolescents' confidence and ability to perform essential diabetes self-management behaviors.

The program focuses on self-management behaviors relevant to DKA prevention, including insulin administration, blood glucose monitoring, dietary management, recognition and management of abnormal blood glucose levels, ketone monitoring, physical activity management, and problem-solving in unexpected situations, including sick-day management.

The study will evaluate whether participation in the SE-LINE program improves adolescents' self-management behaviors for DKA prevention. Changes in the relevant outcomes will be assessed using study instruments administered before and after the intervention.

The findings are expected to contribute to the development of digital health interventions in pediatric diabetes care and provide evidence to support nurses and healthcare professionals in promoting self-efficacy and self-management among adolescents with type 1 diabetes.

02

Conditions studied

  • Diabetic Ketoacidosis Children
  • Mobile Health

Keywords

  • Type 1 Diabetes Mellitus
  • Diabetic Ketoacidosis
  • Self-Efficacy
  • LINE Bot
03

In context

Diabetes Mellitus, Type 1

3,756 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

This study's planned enrollment of 32 is below the median of 40 across 2,822 interventional studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

Chulalongkorn University is the lead sponsor of 322 studies on the registry; 66 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
13 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adolescents aged 13-18 years who have been diagnosed with type 1 diabetes mellitus by a physician for at least 6 months.
  • Have good consciousness and are able to listen, speak, read, and write in Thai.
  • Are able to use the LINE application and have a communication device with internet access.

Exclusion criteria

Exclusion Criteria:

  • Adolescents with severe complications requiring medical treatment, such as acute diabetic ketoacidosis or severe infection.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    KidsCarb LINE Bot Self-Efficacy Program

    Participants in this group will receive a self-efficacy promoting program using the KidsCarb LINE Bot for 2 weeks. The researcher will provide individual instruction on how to use the LINE Bot during a clinic visit. Participants will practice recording blood glucose levels, counting carbohydrates, and calculating insulin doses using the insulin-to-carbohydrate ratio (ICR) and insulin sensitivity factor (ISF). The LINE Bot will provide automated support, and a nurse will conduct telephone follow-up once per week throughout the 2-week intervention period. The program is based on Bandura's self-efficacy concept and aims to strengthen adolescents' confidence and ability to perform diabetes self-management behaviors to prevent diabetic ketoacidosis.

    Behavioral: KidsCarb LINE Bot Self-Efficacy Program

  • Experimental
    Standard nursing care

    Participants in this group will receive standard nursing care provided by the clinic for adolescents with type 1 diabetes mellitus. No additional intervention using the KidsCarb LINE Bot will be provided during the 2-week study period.

    Behavioral: Standard Nursing Care

Interventions

  • BehavioralKidsCarb LINE Bot Self-Efficacy Program

    Participants in this group will receive a self-efficacy promoting program using the KidsCarb LINE Bot for 2 weeks. The researcher will provide individual instruction on how to use the LINE Bot during a clinic visit. Participants will practice recording blood glucose levels, counting carbohydrates, and calculating insulin doses using the insulin-to-carbohydrate ratio (ICR) and insulin sensitivity factor (ISF). The LINE Bot will provide automated support, and a nurse will conduct telephone follow-up once per week throughout the 2-week intervention period. The program is based on Bandura's self-efficacy concept and aims to strengthen adolescents' confidence and ability to perform diabetes self-management behaviors to prevent diabetic ketoacidosis.

  • BehavioralStandard Nursing Care

    Participants in this group will receive standard nursing care provided by the clinic for adolescents with type 1 diabetes mellitus. No additional intervention using the KidsCarb LINE Bot will be provided during the 2-week study period.

06

What researchers measure

Primary outcomes

  1. Self-Management Behaviors for Diabetic Ketoacidosis Prevention

    Self-management behaviors for the prevention of diabetic ketoacidosis among adolescents with type 1 diabetes mellitus will be assessed using a 33-item questionnaire developed by Nattaporn Ontakrai (2016) and adapted by the researcher. The questionnaire covers six domains of self-management behaviors. Each item is scored from 0 to 3: 0 = never, 1 = sometimes, 2 = often, and 3 = always. The total score ranges from 0 to 66, with higher scores indicating better self-management behaviors.

    Time frame: Baseline (before the intervention) and 2 weeks after the intervention

07

Study locations

1 site
  • Faculty of Nursing, Chulalongkorn University
    Bangkok, Pathumwan 10330, Thailand
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2026 to primary completion in Sep 2026, 0 months.

Of 850 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 38. This study's 0 months is below that.

Counting every sponsor, half of 955 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2026
First posted
Nov 19, 2026
StartActual
Sep 25, 2026
Primary completionActual
Sep 25, 2026
CompletionEst.
Jan 30, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07949851
Responsible party
Suwimon Rojnawee, PhD, RN (Principal investigator, Chulalongkorn University) — Principal investigator
First posted
Nov 19, 2026
Start date
Sep 25, 2026
Primary completion
Sep 25, 2026
Completion
Jan 30, 2027 (estimated)
Last update
Nov 19, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion